E. Casirati

Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets

Luca Valenti, C. Bianco, F. Malvestiti, 2021, JHEP reports : innovation in hepatology.

Rare ATG7 genetic variants predispose patients to severe fatty liver disease.

L. N. Valenti, H. Reeves, V. Vaira, 2022, Journal of hepatology.

PNPLA3 as a therapeutic target for fatty liver disease: the evidence to date

A. Cherubini, Luca Valenti, E. Casirati, 2021, Expert opinion on therapeutic targets.

Editorial: Unveiling new horizons for liver steatosis genetic variants beyond hepatocellular carcinoma diagnosis ‐ exploring the potential of HSD17B13 inhibition

Luca Valenti, E. Casirati, 2023, Alimentary pharmacology & therapeutics.

Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women

E. Bugianesi, S. Chokshi, G. Baselli, 2023, Nature Medicine.